News

Catabasis’s small molecule NF-kB inhibitor showed promise in phase 2, and the phase 3 PolarisDMD study (NCT03703882) of edasalonexant is fully enrolled and expected to read out in late 2020.

In addition to no-charge testing, patients may have access to the Detect Muscular Dystrophy program, a counseling program designed to aid health decisions and follow-up care.

Nearly all patients in this cohort achieved a clinically meaningful >3-point increase during the study period, demonstrating a consistent response to the gene therapy.

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health detailed what can currently be surmised about siponimod’s effect in treating patients with SPMS.

Axsome Therapeutics has accelerated the completion of its phase 2/3 trial of AXS-05 in patients with Alzheimer disease agitation, with top-line results now expected to read out in Q2 2020, a full quarter ahead of the prior scheduled time.

Data from the DELOS and SYROS studies of idebenone suggest that investigational DMD treatment has a treatment effect maintained for up to 6 years, which can reduce hospitalizations, bronchopulmonary adverse events, and systemic antibiotic use.

No unexpected safety signals were reported in the post hoc analysis.

After meeting co-primary end points of pain freedom and freedom from the most bothersome symptom, the acute migraine agent has been cleared for a phase 3 trial by the FDA.

The director of the Multiple Sclerosis Program at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the findings of a subanalysis of the EXPAND study of siponimod in patients with secondary progressive multiple sclerosis.

Eligible patients with Duchenne muscular dystrophy may receive the drug while it is under priority review by the FDA.

Patients with multiple sclerosis who reported cannabis use noted that it was helpful in relieving pain, as well as other symptoms, such as sleep, depression, anxiety, and/or stress.

The director of the Sleep Disorders Center and vice chair of the department of neurology at the UCLA David Geffen School of Medicine detailed the comorbidities related to narcolepsy.

The risk of relapse was higher with treatment of mycophenolate mofetil in patients with neuromyelitis optica spectrum disorder and other first-line immunosuppressants, compared to treatment with rituximab.

The chief medical officer at SK Life Science discussed what the clinical community needs to know with cenobamate headed to the market in the second quarter of this year.

Lead author Amrou Sarraj, MD, discussed the findings of an assessment of more than 1900 stroke centers and the challenges in EVT access for stroke care.

Neurology News Network for the week ending March 21, 2020.

Neuro-oncology fellow Ashley Aaroe recounts her experience at Neurology on the Hill, advocating for important changes in neurology health care.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 20, 2020.

"Mind Moments," a podcast from NeurologyLive, brings you exclusive interviews with Barry A. Singer, MD, and Nina Riggins, MD, PhD.

The assistant professor of neurology in the Stroke Division and Department of Neurology at the University of Miami Miller School of Medicine spoke to the current limitations of advanced imaging to aid in the treatment of stroke.